[{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ichnos Glenmark Innovation","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":null,"companyTruncated":"Ichnos Glenmark Innovation \/ Certara"}]

Find Clinical Drug Pipeline Developments & Deals by Ichnos Glenmark Innovation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAPS 2024
                          Not Confirmed
                          AAPS 2024
                          Not Confirmed

                          Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

                          Brand Name : ISB 2001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 18, 2024

                          Lead Product(s) : ISB 2001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Certara

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank